Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in Elderly/Overweight Subjects Apr 20, 2022 7:00am EDT
Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund Apr 18, 2022 7:00am EDT
OLINVYK® data selected as President’s Choice abstract at Annual Regional Anesthesiology and Acute Pain Medicine Meeting and Featured at American Burn Association Annual Meeting Apr 13, 2022 4:05pm EDT
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group Mar 31, 2022 7:02am EDT
Trevena to Release Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022 Mar 30, 2022 7:00am EDT
Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical Jan 27, 2022 9:00am EST
Trevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic Pain Dec 13, 2021 7:00am EST
